← 返回

修饰间充质干细胞作为针对肿瘤细胞的靶向系统的应用

英文原题:Applications of Modified Mesenchymal Stem Cells as Targeted Systems against Tumor Cells.

查看英文原题

Applications of Modified Mesenchymal Stem Cells as Targeted Systems against Tumor Cells.

PubMed 2024/07/16(内容时间) Int J Mol Sci Q1 · IF 5.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

联合基因和细胞治疗是癌症治疗中具有前景的策略。鉴于癌症的复杂性,目前正在积极研究多种方法来对抗这种疾病。使用间充质干细胞(MSCs)已显示出双向的抗肿瘤和促肿瘤作用,因为它们对组织微环境发挥大量免疫/调节效应。MSCs已被广泛研究,以利用其抗肿瘤靶向递送系统。它们可以被基因修饰以过表达基因,并选择性或更有效地消除肿瘤细胞。当前的方法倾向于使用MSCs或其衍生物产生更有效且更安全的疗法;然而,工程化MSCs在实体瘤中取得的效果仍然有限,并取决于若干因素,如细胞来源、转基因和肿瘤靶点。本综述描述了以MSCs作为对抗实体瘤基石为核心的基因和细胞治疗进展,阐述了数十年研究中已探索的不同MSC工程化方法。此外,我们总结了工程化MSCs针对最常见癌症的主要目标,并讨论了靶向治疗与传统治疗相结合的挑战、局限性、风险和优势。

展开英文摘要原文

Combined gene and cell therapy are promising strategies for cancer treatment. Given the complexity of cancer, several approaches are actively studied to fight this disease. Using mesenchymal stem cells (MSCs) has demonstrated dual antitumor and protumor effects as they exert massive immune/regulatory effects on the tissue microenvironment. MSCs have been widely investigated to exploit their antitumor target delivery system. They can be genetically modified to overexpress genes and selectively or more efficiently eliminate tumor cells.

Current approaches tend to produce more effective and safer therapies using MSCs or derivatives; however, the effect achieved by engineered MSCs in solid tumors is still limited and depends on several factors such as the cell source, transgene, and tumor target. This review describes the progress of gene and cell therapy focused on MSCs as a cornerstone against solid tumors, addressing the different MSC-engineering methods that have been approached over decades of research.

Furthermore, we summarize the main objectives of engineered MSCs against the most common cancers and discuss the challenges, limitations, risks, and advantages of targeted treatments combined with conventional ones.

论文信息

作者
Garza Treviño EN、Quiroz Reyes AG、Delgado Gonzalez P、Rojas Murillo JA、Islas JF、Alonso SS、Gonzalez Villarreal CA
第一作者单位
Laboratorio de Terapia Celular, Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León, Av. Dr. José Eleuterio González 235, Monterrey 64460, Nuevo León, Mexico.Mexico
通讯作者单位
Departamento de Ciencias Básicas, Vicerrectoría de Ciencias de la Salud, Universidad de Monterrey, Ignacio Morones Prieto 4500, Jesus M. Garza, San Pedro Garza García 66238, Nuevo León, Mexico.Mexico
文献类型
综述
期刊
International journal of molecular sciences2024 Jul 16
原文标识
PubMed 39063032 · DOI 10.3390/ijms25147791